“We have closed out very good year where our facilities remain in compliance and we continue to invest for the future,” said Pranav Amin, managing director, Alembic Pharmaceuticals
The company had posted a net profit of Rs 288.51 crore for the corresponding period of the previous fiscal.
Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.
In an interview with CNBC-TV18‘s Ekta Batra and Reema Tendulkar, Pranav Amin, Director & President- International Business, Alembic Pharmaceuticals, discussed the company‘s quarterly earnings.
The growth for the international generics, however, remain muted at about 9 percent due to higher base last year.
In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.
Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.